期刊
BRITISH JOURNAL OF CANCER
卷 100, 期 10, 页码 1549-1557出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605052
关键词
fluorouracil; adjuvant therapy; colorectal cancer; pharmacokinetics; pharmacogenetics
类别
资金
- Regione Veneto [934/02/99]
- AIRC Veneto
The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy. One hundred and thirty consecutive, B2 and C Duke's stage colorectal cancer patients were prospectively enrolled. 5FU pharmacokinetics was evaluated at the first cycle. Thymidylate synthase (TYMS) 5'UTR and 3'UTR polymorphisms and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms were assessed in peripheral leukocytes. Univariate and multivariate analyses were applied to evaluate which variables could predict chemotherapy-induced toxicity, disease-free survival (DFS) and overall survival (OS). Multivariate analysis showed that: (a) low 5FU clearance was an independent predictive factor for severe toxicity (OR = 7.32; P<0.0001); (b) high-5FU clearance predicted poorer DFS (HR = 1.96; P = 0.041) and OS (HR = 3.37; P = 0.011); (c) advanced age was associated with shorter DFS (HR = 3.34; P = 0.0008) and OS (HR = 2.66; P = 0.024); (d) the C/C genotype of the MTHFR C677T polymorphism was protective against grade 3-4 toxicity (P = 0.040); (e) none of the TYMS polymorphisms could explain 5FU toxicity or clinical outcome. British Journal of Cancer (2009) 100, 1549-1557. doi: 10.1038/sj.bjc.6605052 www.bjcancer.com Published online 21 April 2009 (C) 2009 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据